Crohn's Disease Clinical Trials

1 - 9 of 9

Genesis AA

The purpose of this study is to compare the genes of African American children and adults who have inflammatory bowel disease (IBD) with the genes of those who do not have IBD. Genes are pieces of hereditary material found in human cells. How an individual’s genes cause intestinal inflammation in IBD is still being tested and not much is known about the association between genes and IBD in individuals with African ancestry. We hope to understand which genes cause IBD and if certain genes can help doctors personalize treatment for patients with IBD. For more information please contact IBDResearch@email.chop.edu. IRB 11-008363

Microbiome Study

We are looking for patients with and without Inflammatory Bowel Disease to participate in an 8 week study on the human microbiome. The microbiome encompasses the trillions of microbes--bacteria, viruses, and other living things that our bodies carry. The study will include 3 study visits to collect clinical information, oral swabs, rectal swabs, stool samples, and blood sample (if applicable). IRB 15-011817

Bio Repository for Patients with Inflammatory Bowel Disease and Other Gastrointestinal Conditions

The purpose of this research study is to collect different types of samples (such as stool, swabs, urine) to form a biorepository. This repository will provide valuable samples from people with and without IBD so that investigators can learn more about the cause of IBD, and different therapies that could be used to treat it. These samples will be used for future gastrointestinal research. Because technology and scientific understanding may advance quickly, it is not yet known what specific studies the samples may be used for. IRB 11-008158

Immunogenetics of Very Early Onset Inflammatory Bowel Disease

The purpose of this research study is to identify genes that are involved in the development of Inflammatory Bowel Disease (IBD) at a young age (less than 8 years of age).  This is a case-control study of IBD patients which compares children with symptoms and/or diagnosis of IBD at <8 years of age with those not diagnosed until  ≥8 years of age, as well as with family members, and other children without a diagnosis of IBD. Samples are collected for testing, such as blood, stool, oral or rectal swabs, and/or tissue samples. IRB 14-010826

Microbiome and Perianal Crohn's Disease

The purpose of this study is to characterize the microbiome in children with Crohn’s disease who have perianal fistula and to compare it to other children with Crohn’s disease who do not have perianal disease. Studying the role of the microbiome in perianal fistula may help us to develop new therapies. IRB 17-014618

Inflammatory Bowel Disease and Yoga

The Center for Pediatric Inflammatory Bowel Disease is conducting a research study to determine if a structured yoga program, in addition to standard medical treatment, improves quality of life in pediatric patients diagnosed with Inflammatory Bowel Disease. Participants between the ages of 10 and 17 will participate in 12 yoga classes, offered once a week at CHOP outpatient locations or in community settings. The classes include relaxation techniques, breathing exercises and yoga poses felt to be beneficial for a healthy digestive system. Participants also answer a series of questionnaires, four times over the course of the study.

VEDOKIDS

This study aims to prospectively explore the real life short and longer term outcomes of Vedolizumab in pediatric inflammatory bowel disease and to develop a prediction model for treatment success based on Vedolizumab trough levels and other clinical and laboratory markers. Children under 18 years of age that have been diagnosed with IBD and their physician is starting treatment with Vedolizumab may be eligible.

Track LIGHT

The TRaCk LIGHT study is a research study that will help doctors and scientists learn whether an investigational medicine can improve the signs and symptoms of Crohn’s disease. The investigational medicine is an injection taken in the abdomen once every 2 weeks that helps block a protein in the intestine that contributes to inflammation. The investigational medicine has not been approved by the US Food and Drug Administration (FDA). You may be able to participate in this study if you are 18 years old or older, have had a diagnosis of Crohn’s disease, and have not responded to or lost response to anti-TNF alpha medicines that treat Crohn’s disease. If interested, please contact Caitlin Walsh at walshc6@email.chop.edu or 267-426-9249.

UC Diet

Announcing a new diet trial for patients with an established diagnosis of UC. Patients ages 8-19 who have mild and stable disease and have never taken a biologic medication (a class of medications including infliximab and adalimumab) might be eligible. For more information, please contact the IBD Center at IBDResearch@email.chop.edu, or call Lindsay Besecker at (267)-426-8414.